TRex Bio files for Nasdaq IPO under ticker TRXB
TRex Bio, a clinical-stage biotech developing immunoregulatory medicines targeting tissue regulatory T cells, filed for an initial public offering and plans to list on Nasdaq Global Select Market under ticker “TRXB.”
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.